MDPI

Article

Rational Design, Synthesis, and Anti-Proliferative Evaluation of Novel 4-Aryl-3,4-Dihydro-2*H*-1,4-Benzoxazines

Xiaoming Fu, Daniel Wenholz, Daniel S. H. Chan, David StC. Black [ID] and Naresh Kumar *[ID]

School of Chemistry, University of New South Wales (UNSW), Kensington, Sydney 2052, Australia; d.black@unsw.edu.au (D.S.B.)
* Correspondence: n.kumar@unsw.edu.au

Abstract: A synthetic pathway to a novel 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazine scaffold was developed and a series of compounds based on the scaffold were synthesised as potential anticancer agents. The 4-aryl-substituted compounds were prepared via Buchwald–Hartwig cross-coupling between substituted bromobenzenes and various 1,4-benzoxazines, which in turn were generated from a cascade hydrogenation and reductive amination one-pot reaction. These analogues exhibited moderate to good potency against various cancer cell lines. Structure–activity relationship analysis indicated that the inclusion of hydroxyl groups on ring A and ring B was beneficial to biological activity, while having a *para*-amino group on ring C significantly enhanced potency. Molecule **14f** displayed the most potent anticancer activity (IC$_{50}$ = 7.84–16.2 μM against PC-3, NHDF, MDA-MB-231, MIA PaCa-2, and U-87 MG cancer cell lines), indicating its potential as a lead compound for further structural optimisation. All the synthesised compounds were fully characterised with NMR, HMRS, and IR. The novel benzoxazine scaffold described in this study holds promise and deserves further in-depth studies.

Keywords: 1,4-benzoxazines; heterocyclic; anticancer; structure activity relationship

1. Introduction

Cancer is one of the leading causes of death worldwide [1]. In 2019, over 1.8 million new cancer cases were diagnosed in the United States [2]. Lung, colorectal, breast, and prostate cancer are the most frequent forms of cancer which contribute to around 30% of all new diagnoses and at least 10% of cancer-related deaths [3].

Conventional approaches for modern drug development heavily rely on the discovery of active compounds against an individual biological target. However, such single-target methods are not always effective at delivering drugs against complex multifactorial diseases such as cancer [4]. To overcome this limitation, one strategy is to design multitarget drugs that are capable of simultaneously and specifically binding to multiple sites within the target system [5,6].

In an effort toward developing novel pharmacophores as anticancer agents, the synthetic *cis*- and *trans*-isoflavanols have attracted much attention [7]. Equol, a molecule possessing a benzopyran pharmacophore, displays low-nanomolar binding affinity to 5α-DHT and reduces the risk of developing prostate-associated disorders [8]. A series of 4-substituted isoflavonoids demonstrated potential pharmacological value by binding avidly to the estrogen receptor [9,10]. After iterative chemical modification, 4-substituted benzopyran compounds demonstrated a progressive increase in broad anticancer activity which was attributed to their potential role as tubulin polymerization inhibitors leading to delayed mitosis as a result [11]. These findings suggest that 4-substituted isoflavan is a promising pharmacophore with broad anticancer potential.

Benzoxazine analogues, particularly 1,4-benzoxazine systems, represent another important class of biologically active compounds with significant pharmaceutical value

against various diseases, including cardiovascular disorders, neurodegeneration, inflammation, and cancer [12–14]. Triazole–benzoxazine hybrids also displayed promising antiproliferative activities [15]. A 1,4-benzoxazine inhibited hypoxic tumours by downregulating hypoxia-induced genes while only exhibiting low toxicity to normoxic cells [16]. 2,3-Dihydro-1,4-benzoxazines were investigated as orally bioavailable anticancer agents via inhibition of angiogenesis [17]. Another type of 2,3-dihydro-1,4-benzoxazine possessed a dual antiangiogenic mechanism via both thrombin and integrin inhibitory activity [18]. A 1,4-benzoxazine sulphonamide was a potent agonist of retinoic acid receptor-related orphan receptor (ROR) and decreased cancer growth via increasing T-cell activity in the tumour microenvironment [19]. 1,4-Benzoxazin-3-one sulphonamides were evaluated as inhibitors of PI3Ka in several cancer cell lines [20,21]. Recently, a tyrosine-based benzoxazine was discovered to show promising anticancer activity via the inducement of breast cancer cell apoptosis [22]. These findings suggest that the 1,4-benzoxazine scaffold is biologically privileged for the development of anticancer agents.

Due to the similarity in the scaffolds of 4-substituted isoflavans and 3,4-dihydro-2*H*-1,4-benzoxazines, we hypothesized that novel 4-aryl substituted 1,4-benzoxazines might display improved toxicity and selectivity against cancer cell lines (Figure 1). In this paper, we designed, synthesised, and examined the in vitro biological activities of a small library of 1,4-benzoxazine derivatives. The reported synthetic path is efficient and enables various modifications so that novel analogues can be easily prepared. The structure–activity relationships (SAR) of these compounds provide guidance to the development of future lead candidates against cancer.


Figure 1. Design of 4-aryl substituted 1,4-benzoxazines as anticancer agents.

2. Results and Discussion

2.1. Chemical Synthesis and Characterization

The methodology for synthesising the benzoxazine scaffold was based on a previously published patent, with some modifications [23]. Notably, the original patent did not detail the incorporation of 4-aryl substitution. The reaction of 2-nitrophenol **1** and 2-bromoacetophenone **2a** and 2-bromo-4′-methoxyacetopheone **2b** under Williamson ether synthesis conditions provided the nitro intermediates **3a** and **3b** in good yield (Scheme 1). The nitro groups of **3a** and **3b** were reduced to amines using Pd/C (as opposed to NaH$_2$PO$_2$) [23], which was followed by intramolecular cyclization via the Mannich reaction to give the 1,4-benzoxazines **4a** and **4b** in a one-pot reaction. Finally, *N*-arylation was performed under modified Buchwald–Hartwig amination conditions with excess substituted bromobenzene to generate the 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazine derivatives **5a–e** in moderate yields of 23–50%.

Scheme 1. Reagents and conditions: (**a**) K_2CO_3, acetone, rt, 6 h, N_2, 72–83%; (**b**) H_2, Pd/C, methanol, rt, 12 h, 50–95%; and (**c**) substituted bromobenzene, $Pd_2(dba)_3$, XPhos, $CsCO_3$, *tert*-butanol, toluene, 100 °C, 16 h, argon, 23–50%.

With the synthesis methodology in hand, we set out to further explore the biological activities of benzoxazines by introducing a 7-methoxy group to the benzoxazine core as well as different substituents on the pendant aromatic ring, and to explore further the biological activities of these benzoxazines. Thus, 5-methoxy-2-nitrophenol **6** was alkylated with various 2-bromoacetophenones **2b**, **7a**, **7b** to provide nitro compounds **8a–c** in 73–90% yield (Scheme 2). The intermediates were subjected to catalytic hydrogenation and intramolecular cyclization to furnish **9a–c**. Interestingly, small amounts of 2*H*-benzoxazines **10a** and **10b** were also isolated in addition to the main dihydrobenzoxazines **9a** and **9c** respectively. Different substitutions were introduced to the pendant 4-aryl group by reacting **9a–c** with various substituted bromobenzenes under similar reaction conditions, furnishing the 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazine compounds **11a–g** in 24–82% yields. When **9a** was coupled with 1-bromo-2,4-dimethoxybenzene in similar conditions, the unsaturated benzoxazine **12** was the only product of the coupling reaction and the anticipated dihydrobenzoxazine was not formed. The variation on the benzoxazine core was evidenced by the absence of the two doublets at around 4.2 ppm corresponding to the protons of methylene at C2 and one triplet at around 5.0 ppm corresponding to the chiral proton of C3. The methylene protons are diastereotopic due to the presence of an adjacent chiral proton which makes them chemically non-equivalent, thus giving rise to two different chemical shifts. The structure was further confirmed by the presence of a singlet at 6.69 ppm integrating for one proton corresponding to the olefinic proton H2 in **12**.

Next, we wanted to evaluate the effect of amino substitution on the biological properties of the scaffold. Thus, various nitro benzoxazine derivatives were reduced by H_2 in the presence of Pd/C in methanol to furnish the amine compounds **13a–e** (Scheme 3).

In search of improved bioactivities for the novel benzoxazines, we further modified the analogues to investigate the effect of having hydroxyl groups in the structure. Various methoxyl benzoxazines were demethylated in the presence of BBr_3 in dichloromethane to afford the hydroxyl derivatives **14a–g** in good yields (Scheme 4).

The effect of heterocycle substitution was another direction we aimed to explore. Analogues **15a** and **15b** were prepared by coupling benzoxazines **9b** and **9c** with 3-bromoquinoline (Scheme 5). Compound **15b** was further demethylated to obtain the hydroxyl compound **15c**.

Scheme 2. Reagents and conditions: (**a**) K_2CO_3, acetone, rt, 6 h, N_2, 62–90%; (**b**) H_2, Pd/C, methanol, rt, 12 h, 50–60%; and (**c**) substituted bromobenzene, $Pd_2(dba)_3$, XPhos, $CsCO_3$, *tert*-butanol, toluene, 100 °C, 16 h, argon, 24–82%.

Scheme 3. Reagents and conditions: H_2, Pd/C, methanol, rt, 12 h, 55–100%.

Scheme 4. Reagents and conditions: BBr_3, DCM, rt, 8 h, N_2, 40–100%.

Scheme 5. Reagents and conditions: (**a**) 3-bromoquinoline, $Pd_2(dba)_3$, Xphos, $CsCO_3$, *tert*-butanol, toluene, 100 °C, 16 h, argon, 55%; (**b**) BBr_3, DCM, rt, 8 h, N_2, 89%.

2.2. In Vitro Cancer Cell Proliferation Inhibitory Activities and Structure–Activity Relationship Study

To assess the cell growth inhibitory effect of the synthesised 1,4-dihydrobenzoxazine derivatives, their effects on cell proliferation were tested against MIA (PaCa-2) pancreatic cancer cells, (MDA-MB-231) breast cancer cells, and (PC-3) prostate cancer cells using an in vitro CellTiter-Glo assay (Table 1). Out of the 29 synthesised molecules, **11a**, **13c**, **13d**, **14a**, **14b**, **14c**, **14d**, **14f**, and **15c** showed >50% activity against MIA PaCa-2 at 25 µM. Compounds **5c**, **5e**, **11a**, and **14c** displayed >40% growth inhibition against MDA-MB-231. For PC-3 cell line, compounds **13c**, **13d**, **14a**, **14f** displayed >25% activity while **14a** and **14f** displayed activity against both MDA-MB-231 and PC-3 cell lines.

Table 1. Cell growth inhibitory effect of the synthesised compounds and their cell growth inhibitory values in different cancer cell lines. Staurosporine (STS) was used as positive control.

Compounds	Cell Growth Inhibition (%)		
	MIA PaCa-2	MDA-MB-231	PC-3
5a	21 ± 4.5	9.1 ± 3.8	13 ± 0.5
5b	30 ± 8.6	15 ± 0.9	0.8 ± 2.2
5c	26 ± 3.9	44 ± 2.1	2.2 ± 0.9
5d	21 ± 7.3	23 ± 1.3	0.2 ± 7.7
5e	59 ± 6.3	53 ± 3.7	1.0 ± 2.8
10a	-4.2 ± 4.4	-7.2 ± 2.4	-2.6 ± 0.6
10b	17 ± 2.7	3.4 ± 1.9	7.2 ± 0.4
11a	91 ± 1.1	42 ± 11	11 ± 2.5
11b	44 ± 4.0	24 ± 0.3	-1.1 ± 1.6
11d	48 ± 4.5	22 ± 5.6	-0.6 ± 3.8
11e	19 ± 3.2	14 ± 2.7	3.6 ± 2.2
11f	33 ± 5.5	19 ± 9.8	-1.3 ± 2.0
11g	12 ± 1.8	28 ± 3.9	-4.9 ± 1.1
12	37 ± 6.4	24 ± 1.0	-5.6 ± 0.3
13a	37 ± 3.8	3.2 ± 3.0	-5.2 ± 0.6
13b	25 ± 12	-1.8 ± 2.9	-12 ± 6.9
13c	59 ± 4.6	0.5 ± 0.1	25 ± 0.0
13d	79 ± 1.5	20 ± 6.7	50 ± 6.2
13e	52 ± 0.7	17 ± 1.5	-18 ± 3.2
14a	88 ± 0.8	62 ± 8.8	25 ± 6.5
14b	57 ± 11	11 ± 0.9	11 ± 3.3
14c	75 ± 15	52 ± 1.6	12 ± 1.8
14d	94 ± 6.5	45 ± 0.9	1.6 ± 5.0
14e	5.6 ± 3.9	-4.8 ± 1.2	-5.3 ± 1.4
14f	99 ± 0.5	78 ± 0.4	98 ± 0.8
14g	63 ± 7.0	14 ± 4.1	-1.6 ± 5.9
15a	72 ± 0.7	36 ± 0.9	12 ± 8.6
15b	46 ± 3.7	28 ± 3.9	1.6 ± 0.5
	IC_{50} (µM)		
STS	0.0221	0.0029	0.0591

Based on the screening data of the novel 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazines against three cancer cell lines, preliminary SAR conclusions could be drawn (Figure 2).

Molecules with OMe (**11a**–**g**) are favoured over H (**5a**–**e**) on the C7-position of ring A, suggesting that electron-donating substitution on R^1 improved activities. For R^2 substitution on ring B, the introduction of 4-F, 4-OMe, and 2,4-dimethyl (**5c**–**e** and **11a**–**g**) lead to general antiproliferative improvements when compared to an unsubstituted ring (**5a** and **5b**). Among these three substitutions, compounds with 4-OMe (**11a** and **11b**, 91% and 44% against MIA PaCa-2, respectively) and 2,4-dimethyl (**11d**, 48%) were favoured over 4-F (**11f** and **11g**, 33% and 12%). These results suggested that the introduction of electron-donating groups at the *para*-position on ring B gave rise to stronger anti-cancer activities than electron-withdrawing *para*-substituents. Meanwhile, no significant difference was observed between 4-OMe and 2,4-dimethyl substituents, suggesting that the anticancer activities might be independent of the strength of the electron-donating groups. However, it should be noted that the introduction of an extra electron-donating methyl group at the 2-position could influence the overall anticancer activity of the compound. The demethylated analogues (**14a**–**g**) displayed superior efficacy over their methylated precursors (**13b**–**e**), suggesting that the presence of hydroxyl groups is beneficial for anticancer activity, with the exception being compound **14e**, which displayed no activity against all tested cell lines. The overall increased activity due to the presence of the hydroxyl groups could be attributed to hydrogen bonding interactions towards the potential binding site. This observation is supported by the binding of genistein, an isoflavone with two hydroxyl groups which allows it to bind to the estrogen receptors, thus exerting its effects against hormone-dependent cancers [24]. Compound **14f** with 4-NH_2 at R^3 exhibited significant improvement on inhibition against MDA-MB-231 (78%) and PC-3 (98%) cell lines when compared to other series, leading us to identify the 4-NH_2 on ring C as a crucial substitution for increasing overall efficacy. It is hypothesized that this class of compounds exhibits anticancer activity with a mechanism similar to those of isoflavones. The precise mechanism of the anticancer activity remains to be explored.


Figure 2. SAR conclusions of the designed 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazine scaffold.

Compound **14f** (Figure 3) which exhibited 95% inhibition against MIA PaCa-2 and PC-3 and around 90% inhibition against the MDA-MB-231 cell line at 25 µM was selected as the lead compound to determine the IC_{50} values in the concentration range of 0.002–50 µM. The IC_{50} values were found to be 9.71, 7.84, 12.9, 9.58, and 16.2 µM corresponding to PC-3, NHDF, MDA-MB-231, MIA PaCa-2, and U-87 MG cancer cells, respectively. The IC_{50} values of a structurally similar anticancer agent Cantrixil were found to be 0.096, 3.72 and 0.205 µM for PC-3, MIA PaCa-2, and U-87 MG cancer cells, respectively [25]. The predicted physiochemical properties of the tested compounds were calculated using online software [26]. The significant parameters can be used as guidance to determine whether these compounds obey the Lipinski rule of five (description of the rule is provided in Table 2). The parameters of all the tested compounds fall within range of the Lipinski rule of five, suggesting these compounds potentially possess good oral bioavailability.

IC$_{50}$

PC-3	9.71 µM
NHDF	7.84 µM
MDA-MB-231	12.9 µM
MIA PaCa-2	9.58 µM
U-87 MG	16.2 µM

14f

Figure 3. IC$_{50}$ of molecule **14f** in cancer cell lines.

Table 2. In silico predicted parameters of the compounds.

Compounds	Lipinski Rule				
	MW	Accept HB	Donor HB	Log P$_{o/w}$	Violation
5a	287.36	1	0	4.04	0
5b	332.35	3	0	3.6	0
5c	317.38	2	0	4.03	0
5d	362.38	4	0	3.43	0
5e	335.37	3	0	4.34	0
10a	269.3	4	0	2.96	0
10b	257.26	4	0	3.28	0
11a	347.41	3	0	4.03	0
11b	377.43	4	0	4	0
11d	375.46	3	0	4.64	0
11e	390.43	4	0	4.08	0
11f	365.4	4	0	4.32	0
11g	380.37	5	0	3.73	0
12	405.44	5	0	4.14	0
13a	302.37	1	1	3.48	0
13b	332.40	2	1	3.47	0
13c	362.42	3	1	3.47	0
13d	360.45	2	1	4.13	0
13e	350.39	3	1	3.79	0
14a	303.35	2	1	3.64	0
14b	318.37	2	2	3.08	0
14c	319.35	3	2	3.22	0
14d	335.35	4	3	2.81	0
14e	334.37	3	3	2.66	0
14f	346.42	2	2	3.71	0
14g	337.34	4	2	3.52	0
15a	396.48	3	0	4.94	0
15b	386.42	4	0	4.61	0

Description: Lipinski rule—Number of violations of Lipinski's rule of five. The rules are as follows: MW < 500, accept HB $\leq$ 10, donor HB < 5, Log P$_{o/w}$ < 5 and maximum 4 violations.

3. Materials and Methods

General procedures

All reagents and solvents were obtained from commercial sources and purified if necessary. Melting points were measured using a Mel-Temp melting point apparatus and are uncorrected. Melting points were measured using an OptiMelt melting point apparatus and are uncorrected. Infrared (IR) spectra were recorded using a Cary 630 FTIR spectrometer or Nicolet[TM] iS[TM] 10 FTIR spectrometer (Thermo Nicolet, Waltham, MA, USA) fitted with a diamond attenuated total reflectance (ATR) sample interface. ^{1}H and ^{13}C NMR spectra were obtained in the specified solvents on a Bruker Avance III HD 400 (Bruker, Sydney, NSW, Australia). Chemical shifts (δ) are in parts per million (ppm) internally referenced to the solvent nuclei. Multiplicities are assigned as singlet (s), broad

singlet (bs), doublet (d), triplet (t), quartet (q), multiplet (m) or a combination of these (e.g., dd, dt, td), and coupling constants (*J*) are reported in Hertz (Hz). High-resolution mass spectrometry (HRMS) was performed using a Thermo LTQ Orbitrap XL instrument (Thermo Scientific, Waltham, MA, USA). ^{1}H and ^{13}C NMR spectra of the synthesised compounds are available in the Supplementary Materials. Thin-layer chromatography (TLC) was performed using 0.25 mm silica gel plates (60F-254). The products were purified by column chromatography on silica gel 60 (63–200 mesh).

In vitro assay

Cytotoxicity was determined using a CellTitre-Glo assay [27]. A stock solution of each compound was prepared at 10 mM in DMSO. IC_{50} values were determined by testing cell growth inhibition across 10 compound concentrations, starting at 50 μM and using 3-fold serial dilution in a 96-well plate. Each compound concentration was tested in duplicate in two independent experiments. DMSO final concentration was normalised at 0.5%. Plates were incubated for 72 h at 37 °C and 5% CO_2. During data analysis, IC_{50} values were calculated with KLFit curve fitting software (version 5.5.0.5) using the 4 Parameter Logistic Model [fit = (A + ((B−A)/(1 + ((C/x)^D))))] (A: Bottom; B: Top; C: Relative IC_{50}; D: Hill).

Experimental Protocols and Analytical Details

General procedure for the synthesis of 2-nitrophenoxyphenylethanones

Anhydrous K_2CO_3 (1.8 eq.) was added to a stirred solution of the corresponding 2-nitrophenol in acetone at room temperature and stirred for 30 min. The corresponding 2-bromo-1-phenylethanone (1.1 eq.) was added to the reaction mixture and stirred at room temperature until the reaction showed signs of completion as indicated by TLC. The reaction mixture was filtered, and the residue was washed with acetone. The combined filtrate was concentrated in vacuo to obtain the crude product. Acetone was added followed by the slow addition of H_2O until solid precipitated out. The solid thus obtained was filtered and dried to obtain the target 2-nitrophenoxyphenylethanone.

2-(2-Nitrophenoxy)-1-phenylethan-1-one (**3a**). Pale brown solid, yield: 83%. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.05–7.98 (m, 2H), 7.90 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.76–7.67 (m, 1H), 7.63–7.54 (m, 3H), 7.30 (dd, *J* = 8.6, 1.1 Hz, 1H), 7.13 (m, 1H), 5.87 (s, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 194.06, 151.17, 140.15, 134.53, 134.46, 129.32, 128.38, 125.36, 121.38, 115.85, 71.54. Data consistent with reported literature [28].

1-(4-Methoxyphenyl)-2-(2-nitrophenoxy)ethan-1-one (**3b**). White solid, yield: 72%. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.03–7.94 (m, 2H), 7.89 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.58 (ddd, *J* = 8.6, 7.4, 1.7 Hz, 1H), 7.25 (dd, *J* = 8.6, 1.1 Hz, 1H), 7.17–7.05 (m, 3H), 5.79 (s, 2H), 3.87 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 192.32, 164.21, 151.28, 140.12, 134.51, 130.76, 127.41, 125.35, 121.29, 115.83, 114.57, 71.23, 56.14. Data consistent with reported literature [28].

2-(5-Methoxy-2-nitrophenoxy)-1-(4-methoxyphenyl)ethan-1-one (**8a**). Pale brown solid, yield: 62%, mp: 147–149 °C. IR (neat) 1681, 1290, 1172 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.03–7.93 (m, 3H), 7.14–7.05 (m, 2H), 6.75 (d, *J* = 2.5 Hz, 1H), 6.69 (dd, *J* = 9.1, 2.5 Hz, 1H), 5.80 (s, 2H), 3.87 (s, 3H), 3.82 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 192.26, 164.64, 164.19, 154.26, 133.21, 130.81, 128.23, 127.49, 114.55, 106.47, 101.69, 71.39, 56.63, 56.13. HRMS (+ESI): Found *m/z* 340.07910, [M + Na]$^+$. $C_{16}H_{15}NO_6Na$ [340.07971].

1-(2,4-Dimethylphenyl)-2-(5-methoxy-2-nitrophenoxy)ethan-1-one (**8b**). Pale yellow solid, yield: 90%, mp: 124–126 °C. IR (neat) 2925, 1679, 1261 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.97 (d, *J* = 9.1 Hz, 1H), 7.87 (d, *J* = 7.7 Hz, 1H), 7.19 (d, *J* = 8.9 Hz, 2H), 6.78–6.63 (m, 2H), 5.70 (s, 2H), 3.82 (s, 3H), 2.39 (s, 3H), 2.34 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 196.66, 164.63, 154.19, 143.05, 138.76, 133.09, 131.94, 129.79, 128.22, 126.89, 106.68, 101.35, 72.42, 56.63, 21.45, 21.28. HRMS (+ESI): Found *m/z* 338.09992, [M + Na]$^+$. $C_{17}H_{17}NO_5Na$ [338.10044].

1-(4-Fluorophenyl)-2-(5-methoxy-2-nitrophenoxy)ethan-1-one (**8c**). White solid, yield: 79%, mp: 173–175 °C. IR (neat) 1684, 1592, 1501 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.15–8.05 (m, 2H), 7.99 (d, *J* = 9.1 Hz, 1H), 7.48–7.37 (m, 2H), 6.80 (d, *J* = 2.5 Hz, 1H), 6.70 (dd, *J* = 9.1, 2.5 Hz, 1H), 5.85 (s, 2H), 3.82 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 192.64, 167.14, 164.68,

164.63, 154.10, 133.21, 131.58, 131.48, 131.41, 131.38, 128.24, 116.49, 116.27, 106.57, 101.72, 71.61, 56.66. HRMS (+ESI): Found *m/z* 328.05918, [M + Na]$^+$. $C_{15}H_{12}FNO_5Na$ [328.05972].

General procedure for the synthesis of 1,4-benzoxazines

Palladium on carbon (10% wt, 0.1 eq) was added to a solution of the corresponding 2-nitrophenoxyphenylethanone in methanol at room temperature and stirred for 16 h. The reaction mixture was filtered through celite and the filtrate was concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain the target 1,4-benzoxazine.

3-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (**4a**). Pale yellow oil, yield: 50%. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.49–7.26 (m, 5H), 6.78–6.66 (m, 3H), 6.59–6.47 (m, 1H), 6.26 (s, 1H), 4.47 (dt, *J* = 7.3, 2.4 Hz, 1H), 4.22 (ddd, *J* = 10.5, 3.1, 1.6 Hz, 1H), 3.90 (dd, *J* = 10.5, 7.5 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 142.70, 140.14, 134.92, 128.39, 127.63, 127.13, 121.19, 116.87, 115.74, 114.89, 69.91, 52.75. Data consistent with reported literature [29].

3-(4-Methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**4b**). Pale yellow oil, yield: 96%. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.39–7.31 (m, 2H), 7.00–6.91 (m, 2H), 6.76–6.68 (m, 3H), 6.53 (ddd, *J* = 7.6, 5.2, 3.8 Hz, 1H), 6.17 (d, *J* = 1.7 Hz, 1H), 4.41 (dt, *J* = 7.5, 2.3 Hz, 1H), 4.19 (ddd, *J* = 10.4, 3.0, 1.7 Hz, 1H), 3.86 (dd, *J* = 10.4, 7.9 Hz, 1H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 159.36, 143.19, 135.51, 132.36, 128.75, 121.58, 117.35, 116.19, 115.41, 114.29, 70.60, 55.57, 52.69. Data consistent with reported literature [30].

7-Methoxy-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**9a**). Pale yellow solid, yield: 60%, mp: 147–149 °C. IR (neat) 3327, 2837, 1507 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.39–7.30 (m, 2H), 6.98–6.90 (m, 2H), 6.69–6.56 (m, 1H), 6.40–6.31 (m, 2H), 5.74 (t, *J* = 1.8 Hz, 1H), 4.31 (dt, *J* = 8.1, 2.3 Hz, 1H), 4.16 (ddd, *J* = 10.4, 2.9, 1.8 Hz, 1H), 3.84 (dd, *J* = 10.4, 8.2 Hz, 1H), 3.75 (s, 3H), 3.63 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.84, 151.65, 143.40, 131.91, 128.65, 128.31, 115.65, 113.79, 106.70, 102.11, 70.51, 55.27, 55.11, 52.33. HRMS (+ESI): Found *m/z* 272.12811, [M + H]+. $C_{16}H_{18}NO_3$ [272.12867].

3-(2,4-Dimethylphenyl)-7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (**9b**). White solid, yield: 95%, mp: 122–124 °C. IR (neat) 3348, 2872, 1504 cm^{-1}. ^{1}H NMR (400 MHz, DMSO) δ 7.31–7.24 (m, 1H), 7.06–6.99 (m, 2H), 6.65–6.58 (m, 1H), 6.39–6.31 (m, 2H), 5.61 (t, *J* = 1.9 Hz, 1H), 4.48 (dt, *J* = 8.2, 2.4 Hz, 1H), 4.18 (ddd, *J* = 10.6, 2.9, 2.0 Hz, 1H), 3.74 (dd, *J* = 10.5, 8.3 Hz, 1H), 3.63 (s, 3H), 2.33 (s, 3H), 2.25 (s, 3H). ^{13}C NMR (101 MHz, DMSO) δ 151.64, 143.37, 136.30, 135.13, 134.64, 130.89, 128.96, 126.73, 126.70, 115.74, 106.70, 102.12, 69.19, 55.29, 49.24, 20.57, 18.66. HRMS (+ESI): Found *m/z* 270.14885, [M + H]$^+$. $C_{17}H_{20}NO_2$ [270.14940].

3-(4-Fluorophenyl)-7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (**9c**). Brown solid: 92%, mp: 122–124 °C. IR (neat) 3363, 2860, 1507 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.51–7.41 (m, 2H), 7.26–7.15 (m, 2H), 6.63 (dt, *J* = 8.6, 1.2 Hz, 1H), 6.40–6.33 (m, 2H), 5.84 (t, *J* = 1.8 Hz, 1H), 4.40 (dt, *J* = 7.9, 2.4 Hz, 1H), 4.19 (ddd, *J* = 10.5, 2.9, 1.7 Hz, 1H), 3.87 (dd, *J* = 10.4, 7.8 Hz, 1H), 3.64 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.32, 160.90, 152.19, 143.88, 136.86, 136.84, 129.65, 129.57, 128.84, 116.17, 115.68, 115.47, 107.32, 102.63, 70.68, 55.74, 52.62. HRMS (+ESI): Found *m/z* 260.10818, [M + H]$^+$. $C_{15}H_{15}FNO_2$ [260.10868].

7-Methoxy-3-(4-methoxyphenyl)-2H-benzo[b][1,4]oxazine (**10a**). White solid: 40%, mp: 128–130 °C. IR (neat) 2970, 2921, 2842 cm^{-1}. ^{1}H NMR (400 MHz, DMSO) δ 7.98–7.90 (m, 2H), 7.25 (d, *J* = 8.5 Hz, 1H), 7.09–7.01 (m, 2H), 6.59 (dd, *J* = 8.5, 2.7 Hz, 1H), 6.53 (d, *J* = 2.7 Hz, 1H), 5.12 (s, 2H), 3.84 (s, 3H), 3.76 (s, 3H). ^{13}C NMR (101 MHz, DMSO) δ 161.91, 159.61, 156.10, 147.58, 128.53, 128.21, 128.05, 114.55, 108.28, 101.45, 62.68, 55.92, 55.86. HRMS (+ESI): Found *m/z* 270.11239, [M + H]$^+$. $C_{16}H_{16}NO_3$ [270.11302].

3-(4-Fluorophenyl)-7-methoxy-2H-benzo[b][1,4]oxazine (**10b**). Yellow crystal: 5%, mp: 145–147 °C. IR (neat) 2966, 1587, 1306 cm^{-1}. ^{1}H NMR (400 MHz, DMSO) δ 8.09–7.97 (m, 2H), 7.38–7.31 (m, 2H), 7.28 (d, *J* = 8.6 Hz, 1H), 6.61 (dd, *J* = 8.6, 2.7 Hz, 1H), 6.54 (d, *J* = 2.6 Hz, 1H), 5.16 (s, 2H), 3.77 (s, 3H). ^{13}C NMR (101 MHz, DMSO) δ 165.38, 162.90, 160.08, 155.60, 147.61, 132.11, 132.08, 129.28, 129.20, 128.59, 127.75, 116.27, 116.05, 108.41, 101.47, 62.78, 55.97. HRMS (+ESI): Found *m/z* 258.09252, [M + H]$^+$. $C_{15}H_{13}FNO_2$ [258.09303].

General procedure A for the synthesis of 3,4-diphenyl-1,4-benzoxazines

A Schlenk flask was charged with caesium carbonate (1.4 eq.), the corresponding 1,4-benzoxazine, and bromophenol (1.6 eq.). The flask was vacuumed and backfilled with nitrogen three times before the reaction mixture was dissolved in toluene and *tert*-butanol and stirred for 10 min at room temperature. $Pd_2(dba)_3$ (0.02 eq.) and XPhos (0.1 eq.) were added to the solution and the mixture was refluxed until the reaction showed signs of completion as indicated by TLC. The mixture was cooled to room temperature and diluted with ethyl acetate. The solution was washed with brine and water before being dried with sodium sulphate and concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain the target 3,4-diphenyl-1,4-benzoxazine.

General procedure B for the synthesis of 3,4-diphenyl-1,4-benzoxazines

A Schlenk flask was charged with potassium *tert*-butoxide (1.5 eq.), the corresponding 1,4-benzoxazine, and bromophenol (1.6 eq.). The flask was vacuumed and back filled with nitrogen for three times before the reaction mixture was dissolved in toluene and stirred for 10 min at room temperature. Palladium acetate (0.05 eq.) and tri-*tert*-butylphosphine (0.1 eq.) was added to the solution and the mixture was refluxed until the reaction showed signs of completion as indicated by TLC. The mixture was cooled to room temperature and diluted with ethyl acetate. The solution was washed with brine and water before drying with sodium sulphate and then concentrated in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain target 3,4-diphenyl-1,4-benzoxazine.

3,4-Diphenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (**5a**). White solid, yield: 50%, mp: 166–168 °C. IR (neat) 2936, 2167, 1493 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.37–7.26 (m, 6H), 7.27–7.16 (m, 3H), 7.12–7.03 (m, 1H), 6.87 (dd, *J* = 8.1, 1.6 Hz, 1H), 6.83–6.72 (m, 2H), 6.69 (td, *J* = 7.5, 1.6 Hz, 1H), 5.05 (t, *J* = 3.1 Hz, 1H), 4.48 (dd, *J* = 11.0, 3.3 Hz, 1H), 4.30 (dd, *J* = 11.0, 2.8 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 146.25, 144.65, 140.33, 132.83, 129.93, 128.87, 127.67, 127.40, 124.50, 124.48, 121.74, 119.73, 117.22, 116.19, 68.86, 60.66. HRMS (+ESI): Found *m/z* 288.13830, [M + H]+. $C_{20}H_{18}NO$ [288.13884].

4-(4-Nitrophenyl)-3-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (**5b**). Orange solid, yield: 43%, mp: 167–169 °C. IR (neat) 2928, 1583, 1490 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.23–8.14 (m, 2H), 7.45–7.36 (m, 1H), 7.40–7.30 (m, 6H), 7.27 (ddd, *J* = 9.7, 5.1, 2.3 Hz, 1H), 6.96–6.86 (m, 2H), 6.87–6.79 (m, 1H), 5.37 (d, *J* = 2.4 Hz, 1H), 4.78 (dd, *J* = 11.4, 2.0 Hz, 1H), 4.39 (dd, *J* = 11.4, 2.8 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 152.11, 146.10, 141.02, 138.60, 129.16, 128.01, 127.88, 126.95, 126.08, 123.47, 121.63, 119.66, 119.57, 117.87, 68.32, 59.16. HRMS (+ESI): Found *m/z* 333.12349, [M + H]$^+$. $C_{20}H_{17}N_2O_3$ [333.12392].

3-(4-Methoxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (**5c**). Pale yellow crystal, yield: 47%, mp: 152–154 °C. IR (neat) 2906, 1489, 1248 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.38–7.27 (m, 2H), 7.21 (ddd, *J* = 15.6, 7.6, 1.7 Hz, 4H), 7.12–7.03 (m, 1H), 6.89–6.64 (m, 6H), 4.97 (t, *J* = 3.3 Hz, 1H), 4.42 (dd, *J* = 10.9, 3.8 Hz, 1H), 4.26 (dd, *J* = 10.9, 2.8 Hz, 1H), 3.70 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.86, 146.20, 144.63, 133.08, 131.96, 129.89, 128.63, 124.72, 124.53, 121.66, 119.65, 117.15, 116.15, 114.27, 69.04, 60.01, 55.46. HRMS (+ESI): Found *m/z* 318.14909, [M + H]$^+$. $C_{21}H_{20}NO_2$ [318.14940].

3-(4-Methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**5d**). Orange solid, yield: 50%, mp: 107–109 °C. IR (neat) 2833, 2161, 2044 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.23–8.14 (m, 2H), 7.43–7.31 (m, 3H), 7.30–7.23 (m, 2H), 6.92–6.81 (m, 5H), 5.28 (d, *J* = 2.6 Hz, 1H), 4.72 (dd, *J* = 11.4, 2.1 Hz, 1H), 4.36 (dd, *J* = 11.4, 2.8 Hz, 1H), 3.71 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.54, 151.62, 145.63, 140.48, 129.75, 127.68, 127.54, 125.59, 122.96, 121.08, 119.16, 119.06, 117.36, 114.10, 67.90, 58.15, 55.05. HRMS (+ESI): Found *m/z* 363.13424, [M + H]$^+$. $C_{21}H_{19}N_2O_4$ [363.13448].

4-(4-Fluorophenyl)-3-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**5e**). Pale yellow solid, yield: 23%, mp: 101–103 °C. IR (neat) 2928, 1495, 1213 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.25–7.11 (m, 9H), 6.88–6.78 (m, 3H), 6.78–6.63 (m, 2H), 6.61 (dd, *J* = 7.9, 1.7 Hz, 1H), 4.91 (dd, *J* = 4.5, 2.9 Hz, 1H), 4.36 (dd, *J* = 10.9, 4.6 Hz, 1H), 4.27 (dd, *J* = 10.9, 2.9 Hz, 1H), 3.70 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.95, 144.43, 142.26,

142.23, 134.20, 131.59, 131.24, 131.16, 128.88, 128.11, 128.03, 121.76, 119.38, 117.06, 116.74, 116.52, 115.99, 115.78, 115.54, 114.27, 69.33, 60.26, 55.45. HRMS (+ESI): Found m/z 336.13957, $[M + H]^+$. $C_{21}H_{19}FNO_2$ [336.13998].

7-Methoxy-3-(4-methoxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11a**). Orange oil, yield: 38%. IR (neat) 2935, 2836, 1502 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.86–7.76 (m, 1H), 7.52–7.42 (m, 1H), 7.31–7.24 (m, 3H), 7.17–7.09 (m, 2H), 6.99 (tt, J = 7.2, 1.2 Hz, 1H), 6.89–6.81 (m, 2H), 6.45–6.37 (m, 2H), 4.93 (t, 1H), 4.50 (dd, J = 11.0, 3.3 Hz, 1H), 4.21 (dd, J = 11.0, 2.8 Hz, 1H), 3.70 (s, 3H), 3.65 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.80, 153.82, 147.64, 145.91, 131.76, 129.81, 128.54, 125.26, 123.23, 122.84, 118.82, 114.26, 107.71, 102.75, 68.44, 59.80, 55.67, 55.47. HRMS (+ESI): Found m/z 348.15951, $[M + H]^+$. $C_{22}H_{22}NO_3$ [348.15997].

7-Methoxy-3,4-bis(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11b**). Red oil, yield: 82%. IR (neat) 2931, 1596, 1501 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.27–7.19 (m, 2H), 7.11–7.03 (m, 2H), 6.90–6.79 (m, 4H), 6.48 (d, J = 8.9 Hz, 1H), 6.42 (d, J = 2.8 Hz, 1H), 6.35 (dd, J = 8.9, 2.8 Hz, 1H), 4.79 (dd, J = 5.0, 2.8 Hz, 1H), 4.34 (dd, J = 10.9, 5.0 Hz, 1H), 4.21 (dd, J = 10.9, 2.9 Hz, 1H), 3.70 (d, J = 1.2 Hz, 6H), 3.64 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.86, 156.48, 153.01, 145.24, 140.07, 131.73, 128.97, 128.48, 127.17, 117.18, 115.06, 114.17, 107.52, 102.82, 69.37, 60.42, 55.71, 55.61, 55.44. HRMS (+ESI): Found m/z 378.16984, $[M + H]^+$. $C_{23}H_{24}NO_4$ [378.17053].

7-Methoxy-3-(4-methoxyphenyl)-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11c**). Red oil, yield: 24%. IR (neat) 2923, 1598, 1495 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.20–8.11 (m, 2H), 7.31–7.24 (m, 5H), 6.94–6.85 (m, 2H), 6.52 (dd, J = 9.0, 2.8 Hz, 1H), 6.42 (d, J = 2.8 Hz, 1H), 5.31 (s, 1H), 4.77 (dd, J = 11.5, 1.9 Hz, 1H), 4.33 (dd, J = 11.4, 2.8 Hz, 1H), 3.70 (d, J = 11.3 Hz, 6H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.99, 156.12, 152.65, 147.36, 140.08, 129.91, 128.20, 126.20, 121.76, 120.43, 118.10, 114.54, 108.03, 102.68, 68.25, 58.23, 55.73, 55.53. HRMS (+ESI): Found m/z 393.14461, $[M + H]^+$. $C_{22}H_{21}N_2O_5$ [393.14505].

3-(2,4-Dimethylphenyl)-7-methoxy-4-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11d**). Light brown gum, yield: 38%. IR (neat) 2921, 1586, 1501 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.18–7.13 (m, 1H), 7.13–7.06 (m, 2H), 6.89 (d, J = 6.7 Hz, 2H), 6.87–6.81 (m, 2H), 6.46 (dd, J = 7.9, 2.8 Hz, 1H), 6.38 (d, J = 8.8 Hz, 1H), 6.33 (dd, J = 8.9, 2.7 Hz, 1H), 5.00 (dd, J = 5.9, 3.0 Hz, 1H), 4.25 (dd, J = 11.0, 3.1 Hz, 1H), 4.17 (dd, J = 11.0, 5.9 Hz, 1H), 3.69 (s, 3H), 3.65 (s, 3H), 2.24 (s, 3H), 2.18 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.90, 152.66, 144.90, 139.31, 136.50, 135.29, 134.41, 131.49, 130.19, 128.28, 128.09, 126.96, 115.96, 115.01, 107.40, 102.94, 69.02, 57.27, 55.75, 55.56, 20.97, 19.25. HRMS (+ESI): Found m/z 376.19085, $[M + H]^+$. $C_{24}H_{26}NO_3$ [376.19127].

3-(2,4-Dimethylphenyl)-7-methoxy-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11e**). Red solid, yield: 78%, mp: 121–123 °C. IR (neat) 2929, 1585, 1493 cm^{-1}. ^{1}H NMR (400 MHz, Chloroform-d) δ 8.15–8.06 (m, 2H), 7.30 (d, J = 8.6 Hz, 1H), 7.19–7.12 (m, 2H), 7.09–7.06 (m, 1H), 7.04 (d, J = 7.9 Hz, 1H), 6.94–6.87 (m, 1H), 6.61–6.53 (m, 2H), 5.11 (t, J = 3.6 Hz, 1H), 4.47–4.39 (m, 1H), 4.35 (dd, J = 11.0, 3.5 Hz, 1H), 3.81 (s, 3H), 2.42 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 155.74, 152.55, 147.71, 141.04, 137.72, 133.65, 133.30, 132.04, 127.42, 126.61, 125.55, 122.89, 119.79, 118.57, 108.20, 103.00, 68.33, 58.86, 55.60, 31.60, 22.67, 20.97, 19.29, 14.14. HRMS (+ESI): Found m/z 391.16525, $[M + H]^+$. $C_{23}H_{23}N_2O_4$ [391.16578].

3-(2,4-Dimethylphenyl)-7-methoxy-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**15a**). Yellow solid, yield: 55%, mp: 112–114 °C. IR (neat) 2923, 1587, 1505 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.79 (d, J = 2.6 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.82 (dd, J = 8.3, 1.4 Hz, 1H), 7.63 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.52 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 6.95 (d, J = 1.8 Hz, 1H), 6.91–6.82 (m, 1H), 6.76 (d, J = 8.9 Hz, 1H), 6.53 (d, J = 2.9 Hz, 1H), 6.43 (dd, J = 8.9, 2.9 Hz, 1H), 5.32 (d, J = 3.7 Hz, 1H), 4.41–4.26 (m, 2H), 3.69 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 153.93, 149.67, 145.91, 144.82, 140.22, 136.84, 135.37, 134.10, 131.80, 128.95, 128.71, 128.65, 128.36, 127.89, 127.63, 127.40, 127.24, 127.06, 116.96, 107.83, 103.22, 68.51, 57.39, 55.79, 20.94, 19.33. HRMS (+ESI): Found m/z 397.19073, $[M + H]^+$. $C_{26}H_{25}N_2O_2$ [397.19160].

3-(4-Fluorophenyl)-7-methoxy-4-(4-methoxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11f**). Yellow oil, yield: 83%. IR (neat) 2938, 2835, 1501 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.41–7.31 (m, 2H), 7.16–7.03 (m, 4H), 6.91–6.82 (m, 2H), 6.53 (d, J = 8.9 Hz, 1H), 6.44 (d, J = 2.8 Hz, 1H), 6.37 (dd, J = 8.9, 2.8 Hz, 1H), 4.88 (t, J = 3.7 Hz, 1H), 4.38 (dd, J = 10.9, 4.6 Hz, 1H), 4.24 (dd, J = 10.9, 2.8 Hz, 1H), 3.70 (s, 3H), 3.65 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.00, 160.58, 156.54, 153.13, 145.23, 140.07, 136.26, 136.23, 129.80, 129.72, 128.03, 127.03, 117.37, 115.65, 115.44, 115.13, 107.72, 102.86, 68.99, 60.48, 55.70, 55.62. HRMS (+ESI): Found *m/z* 388.13199, [M + Na]$^+$. C$_{22}$H$_{20}$FNO$_3$Na [388.13249].

3-(4-Fluorophenyl)-7-methoxy-4-(4-nitrophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**11g**). Yellow solid, yield: 33%, mp: 139–141 °C. IR (neat) 2912, 1589, 1494 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.21–8.08 (m, 2H), 7.45–7.36 (m, 2H), 7.35–7.24 (m, 3H), 7.24–7.12 (m, 2H), 6.53 (dd, J = 9.0, 2.8 Hz, 1H), 6.43 (d, J = 2.8 Hz, 1H), 5.38 (s, 1H), 4.81 (dd, J = 11.5, 1.9 Hz, 1H), 4.34 (dd, J = 11.5, 2.8 Hz, 1H), 3.69 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.10, 160.68, 156.18, 152.65, 147.29, 140.27, 134.45, 134.42, 129.15, 129.07, 126.19, 121.93, 120.24, 118.28, 116.03, 115.82, 108.20, 102.70, 68.09, 58.30, 55.73. HRMS (+ESI): Found *m/z* 403.10655, [M + Na]$^+$. C$_{21}$H$_{17}$FN$_2$O$_4$Na [403.10700].

3-(4-Fluorophenyl)-7-methoxy-2H-benzo[b][1,4]oxazine (**12**). Dark purple solid: 35%, mp: 159–161 °C. IR (neat) 2989, 2935, 2834 cm^{-1}. ^{1}H NMR (400 MHz, DMSO) δ 7.83–7.72 (m, 2H), 7.34 (d, J = 8.6 Hz, 1H), 7.04–6.93 (m, 2H), 6.72 (d, J = 8.5 Hz, 2H), 6.69 (s, 2H), 6.65 (d, J = 2.4 Hz, 1H), 6.56 (dd, J = 8.6, 2.7 Hz, 1H), 6.36 (d, J = 2.7 Hz, 1H), 6.32 (dd, J = 8.6, 2.4 Hz, 1H), 3.95 (s, 3H), 3.77 (s, 3H), 3.69 (s, 6H). ^{13}C NMR (101 MHz, DMSO) δ 162.12, 161.70, 160.02, 158.53, 156.13, 145.90, 129.79, 128.34, 128.12, 128.07, 127.76, 116.04, 114.59, 108.16, 105.44, 102.18, 99.64, 66.66, 56.49, 55.82, 55.80, 55.70. HRMS (+ESI): Found *m/z* 406.16517, [M + H]$^+$. C$_{24}$H$_{24}$NO$_5$ [406.16545].

3-(4-Fluorophenyl)-7-methoxy-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine (**15b**). Brown gum, yield: 67%. IR (neat) 3078, 3002, 1507 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.83 (d, J = 2.6 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 7.5 Hz, 1H), 7.61 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.55–7.44 (m, 3H), 7.21–7.11 (m, 2H), 7.02–6.95 (m, 1H), 6.51–6.44 (m, 2H), 5.26 (s, 1H), 4.64 (dd, J = 11.2, 3.1 Hz, 1H), 4.34 (dd, J = 11.2, 2.7 Hz, 1H), 3.69 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.07, 160.65, 154.77, 148.15, 146.49, 144.34, 141.22, 135.56, 135.53, 129.55, 129.47, 128.94, 128.79, 128.16, 127.70, 127.49, 125.34, 123.92, 119.52, 115.88, 115.67, 108.20, 102.96, 67.97, 59.71, 55.72. HRMS (+ESI): Found *m/z* 387.15037, [M + H]$^+$. C$_{24}$H$_{20}$FN$_2$O$_2$ [387.15088].

General procedure for the synthesis of 3-phenyl-4-aniline-1,4-benzoxazine

Palladium on carbon (10% wt, 0.1 eq.) was added to a solution of the corresponding 3-phenyl-4-aniline-1,4-benzoxazine in methanol at room temperature and stirred for 16 h. The reaction mixture was filtered through celite and the filtrate removed in vacuo to obtain crude product, which was purified by flash chromatography (hexane/ethyl acetate) to obtain target 3-phenyl-4-aniline-1,4-benzoxazine.

4-(3-Phenyl-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (**13a**). Brown solid, yield: 85%, mp: 169–171 °C. IR (neat) 3454, 3374, 2920 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.33–7.15 (m, 5H), 6.89–6.81 (m, 2H), 6.76 (dd, J = 7.8, 1.5 Hz, 1H), 6.68 (ddd, J = 8.0, 7.3, 1.6 Hz, 1H), 6.57 (td, J = 7.6, 1.6 Hz, 1H), 6.53–6.41 (m, 3H), 5.00 (s, 2H), 4.83 (t, J = 3.8 Hz, 1H), 4.32–4.21 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 146.59, 143.41, 140.24, 135.86, 133.58, 128.20, 127.96, 127.38, 127.17, 121.34, 117.26, 116.16, 114.52, 114.15, 69.15, 61.04. HRMS (+ESI): Found *m/z* 303.14921, [M + H]$^+$. C$_{20}$H$_{19}$N$_2$O [303.14974].

4-(3-(4-Methoxyphenyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (**13b**). Yellow solid, yield: 78%, mp: 170–172 °C. IR (neat) 3456, 3371, 2932 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.23–7.15 (m, 2H), 6.87–6.79 (m, 4H), 6.76 (dd, J = 7.8, 1.6 Hz, 1H), 6.71–6.62 (m, 1H), 6.56 (td, J = 7.5, 1.6 Hz, 1H), 6.52–6.44 (m, 2H), 6.41 (dd, J = 8.0, 1.5 Hz, 1H), 5.00 (s, 2H), 4.75 (t, J = 4.0 Hz, 1H), 4.22 (d, J = 4.0 Hz, 2H), 3.70 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.85, 147.04, 143.91, 136.60, 133.99, 132.29, 129.07, 128.59, 121.72, 117.74, 116.56, 114.98, 114.73, 114.07, 69.87, 60.74, 55.42. HRMS (+ESI): Found *m/z* 333.15971, [M + H]$^+$. C$_{21}$H$_{21}$N$_2$O$_2$ [333.16030].

4-(7-Methoxy-3-(4-methoxyphenyl)-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (**13c**). Dark-brown solid, yield: 100%, mp: 142–144 °C. IR (neat) 3448, 2929, 2837 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.28–7.13 (m, 2H), 6.88–6.73 (m, 4H), 6.50–6.42 (m, 2H), 6.42–6.25 (m, 3H), 4.93 (s, 2H), 4.68 (dd, *J* = 5.6, 3.0 Hz, 1H), 4.32–4.13 (m, 2H), 3.70 (s, 3H), 3.63 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 158.82, 152.40, 146.54, 144.82, 135.40, 132.00, 130.17, 129.14, 127.96, 116.46, 114.98, 114.05, 107.33, 102.75, 69.89, 60.59, 55.72, 55.41. HRMS (+ESI): Found *m/z* 363.17036, [M + H]$^+$. $C_{22}H_{23}N_2O_3$ [363.17087].

4-(3-(2,4-Dimethylphenyl)-7-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (**13d**). Brown solid, yield: 75%, mp: 119–121 °C. IR (neat) 3466, 3377, 2883 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 7.17 (d, *J* = 7.8 Hz, 1H), 6.93–6.85 (m, 2H), 6.86–6.78 (m, 2H), 6.48–6.37 (m, 3H), 6.30 (d, *J* = 1.6 Hz, 2H), 4.94 (s, 2H), 4.91 (dd, *J* = 6.4, 3.0 Hz, 1H), 4.22 (dd, *J* = 10.9, 3.0 Hz, 1H), 4.12 (dd, *J* = 10.9, 6.4 Hz, 1H), 3.64 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 152.21, 146.82, 144.62, 136.36, 135.33, 134.85, 134.56, 131.40, 131.35, 128.52, 128.30, 126.89, 115.76, 114.95, 107.23, 102.83, 69.29, 57.17, 55.75, 20.99, 19.26. HRMS (+ESI): Found *m/z* 361.19108, [M + H]$^+$. $C_{23}H_{25}N_2O_2$ [361.19160].

4-(3-(4-Fluorophenyl)-7-methoxy-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)aniline (**13e**). Dark-brown solid, yield: 43%, mp: 128–130 °C. IR (neat) 3455, 3364, 2836 cm^{-1}. ^{1}H NMR (400 MHz, Chloroform-*d*) δ 7.32–7.23 (m, 2H), 7.04–6.93 (m, 2H), 6.97–6.89 (m, 2H), 6.65–6.57 (m, 3H), 6.52 (d, *J* = 2.8 Hz, 1H), 6.39 (dd, *J* = 8.9, 2.8 Hz, 1H), 4.68 (dd, *J* = 5.1, 3.1 Hz, 1H), 4.37 (dd, *J* = 10.8, 5.1 Hz, 1H), 4.31 (dd, *J* = 10.8, 3.1 Hz, 1H), 3.75 (s, 3H), 3.64 (s, 2H). ^{13}C NMR (101 MHz, CDCl$_3$) δ 163.35, 160.91, 152.98, 144.97, 143.41, 138.35, 135.41, 135.38, 129.16, 129.08, 128.72, 127.54, 117.25, 116.08, 115.46, 115.24, 107.56, 102.61, 69.38, 61.52, 55.67. HRMS (+ESI): Found *m/z* 351.15036, [M + H]$^+$. $C_{21}H_{20}FN_2O_2$ [351.15088].

General procedure for demethylation using BBr$_3$

BBr$_3$ (1M) in dichloromethane solution (2 eq. per methoxy group) was added to a solution of the corresponding methylated 3,4-diphenyl-1,4-benzoxazine in dichloromethane at 0 °C and stirred for 12 h. The reaction mixture was quenched with saturated sodium bicarbonate solution and diluted with ethyl acetate. The solution was washed with brine and water before drying with sodium sulphate and concentrated in vacuo to obtain crude product, which was purified by flash chromatography (dichloromethane/methanol) to obtain target demethylated 3,4-diphenyl-1,4-benzoxazine.

4-(4-Phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)phenol (**14a**). White solid, yield: 67%, mp: 150–152 °C. IR (neat) 3516, 1586, 1490 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.32 (s, 1H), 7.37–7.27 (m, 2H), 7.22–7.14 (m, 2H), 7.14–7.03 (m, 3H), 6.83–6.62 (m, 6H), 4.90 (t, *J* = 3.3 Hz, 1H), 4.38 (dd, *J* = 10.9, 3.9 Hz, 1H), 4.25 (dd, *J* = 10.9, 2.8 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.97, 146.22, 144.62, 133.29, 130.12, 129.85, 128.62, 124.92, 124.55, 121.61, 119.53, 117.10, 116.08, 115.59, 69.13, 60.10. HRMS (+ESI): Found *m/z* 304.13317, [M + H]$^+$. $C_{20}H_{18}NO_2$ [304.13375].

4-(4-(4-Aminophenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)phenol (**14b**). Brown solid, yield: 62%, mp: 113–115 °C. IR (neat) 3438, 3352, 2884 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.28 (s, 1H), 7.10–7.02 (m, 2H), 6.85–6.77 (m, 2H), 6.75 (dd, *J* = 7.8, 1.6 Hz, 1H), 6.69–6.60 (m, 3H), 6.55 (td, *J* = 7.5, 1.6 Hz, 1H), 6.52–6.44 (m, 2H), 6.39 (dd, *J* = 8.1, 1.6 Hz, 1H), 4.99 (s, 2H), 4.68 (t, *J* = 4.1 Hz, 1H), 4.22–4.18 (m, 2H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.95, 146.98, 143.91, 136.72, 134.06, 130.49, 129.04, 128.68, 121.67, 117.65, 116.52, 115.42, 114.97, 114.70, 69.94, 60.84. HRMS (+ESI): Found *m/z* 319.14402, [M + H]$^+$. $C_{20}H_{19}N_2O_2$ [319.14465].

3-(4-Hydroxyphenyl)-4-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (**14c**). Brown solid, yield: 40%, mp: 129–131 °C. IR (neat) 3189, 3927, 2865 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.30 (s, 1H), 8.92 (s, 1H), 7.31–7.21 (m, 2H), 7.17–7.06 (m, 4H), 6.96 (tt, *J* = 7.1, 1.1 Hz, 1H), 6.73 (d, *J* = 8.5 Hz, 1H), 6.71–6.62 (m, 2H), 6.27–6.19 (m, 2H), 4.84 (t, *J* = 3.0 Hz, 1H), 4.43 (dd, *J* = 11.0, 3.4 Hz, 1H), 4.16 (dd, *J* = 11.0, 2.8 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.85, 151.84, 148.11, 146.04, 130.05, 129.69, 128.52, 123.77, 122.78, 122.58, 119.28, 115.54, 108.79, 103.97, 68.27, 59.93. HRMS (+ESI): Found *m/z* 342.11001, [M + Na]$^+$. $C_{20}H_{17}NO_3Na$ [342.11061].

4,4′-(7-Hydroxy-2,3-dihydro-4H-benzo[b][1,4]oxazine-3,4-diyl)diphenol (**14d**). Black solid, yield: 70%, mp: 91–93 °C. IR (neat) 3023, 2814, 2692 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.28 (s, 1H), 9.22 (s, 1H), 8.74 (s, 1H), 7.12–7.04 (m, 2H), 6.95–6.87 (m, 2H), 6.69–6.59 (m, 4H), 6.30 (d, *J* = 8.7 Hz, 1H), 6.22 (d, *J* = 2.6 Hz, 1H), 6.15 (dd, *J* = 8.7, 2.7 Hz, 1H), 4.62 (dd, *J* = 5.5, 2.9 Hz, 1H), 4.24 (dd, *J* = 10.8, 5.5 Hz, 1H), 4.14 (dd, *J* = 10.8, 2.9 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.90, 154.62, 150.61, 145.15, 138.92, 130.08, 129.05, 127.88, 127.65, 117.31, 116.23, 115.42, 108.57, 103.88, 69.52, 60.68. HRMS (+ESI): Found *m/z* 358.10491, [M + Na]$^+$. C$_{20}$H$_{17}$NO$_4$Na [358.10553].

4-(4-Aminophenyl)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (**14e**). Black gum, yield: 75%. IR (neat) 2929, 1596, 1502 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.26 (s, 1H), 8.68 (s, 1H), 7.13–6.99 (m, 2H), 6.82–6.71 (m, 2H), 6.68–6.57 (m, 2H), 6.50–6.39 (m, 2H), 6.28–6.18 (m, 2H), 6.13 (dd, *J* = 8.7, 2.7 Hz, 1H), 4.89 (s, 2H), 4.56 (dd, *J* = 5.8, 3.1 Hz, 1H), 4.19 (dd, *J* = 10.8, 5.8 Hz, 1H), 4.13 (dd, *J* = 10.8, 3.1 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 156.87, 150.21, 146.30, 144.93, 135.98, 130.24, 129.15, 128.89, 127.94, 116.93, 115.36, 114.92, 108.46, 103.80, 69.87, 60.76. HRMS (+ESI): Found *m/z* 335.13894, [M + H]$^+$. C$_{20}$H$_{19}$N$_2$O$_3$ [335.13957].

4-(4-Aminophenyl)-3-(2,4-dimethylphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (**14f**). Pale-brown Solid, yield: 89%, mp: 185–187 °C. IR (neat) 3373, 3304, 2920 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.67 (s, 1H), 7.18 (d, *J* = 7.8 Hz, 1H), 6.94–6.84 (m, 2H), 6.84–6.74 (m, 2H), 6.47–6.37 (m, 2H), 6.24 (d, *J* = 2.6 Hz, 1H), 6.20 (d, *J* = 8.7 Hz, 1H), 6.13 (dd, *J* = 8.7, 2.6 Hz, 1H), 4.91 (s, 2H), 4.86 (dd, *J* = 6.7, 3.0 Hz, 1H), 4.17 (dd, *J* = 10.9, 3.0 Hz, 1H), 4.08 (dd, *J* = 10.9, 6.7 Hz, 1H), 2.22 (s, 3H), 2.18 (s, 3H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 150.05, 146.65, 144.70, 136.28, 135.35, 135.29, 134.57, 131.30, 130.05, 128.47, 128.39, 126.87, 116.20, 114.90, 108.45, 103.85, 69.30, 57.18, 20.99, 19.28. HRMS (+ESI): Found *m/z* 347.17541, [M + H]$^+$. C$_{22}$H$_{23}$N$_2$O$_2$ [347.17595].

3-(4-Fluorophenyl)-4-(4-hydroxyphenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (**14g**). Brown gum, yield: 95%. IR (neat) 3401, 1698, 1502 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.25 (s, 1H), 8.79 (s, 1H), 7.40–7.30 (m, 2H), 7.14–7.04 (m, 2H), 6.97–6.89 (m, 2H), 6.71–6.62 (m, 2H), 6.38 (d, *J* = 8.7 Hz, 1H), 6.24 (d, *J* = 2.6 Hz, 1H), 6.19 (dd, *J* = 8.7, 2.7 Hz, 1H), 4.78 (dd, *J* = 5.0, 2.8 Hz, 1H), 4.31 (dd, *J* = 10.9, 5.0 Hz, 1H), 4.18 (dd, *J* = 10.9, 2.8 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 162.95, 160.53, 154.68, 150.83, 145.16, 138.95, 136.41, 136.38, 129.89, 129.81, 127.32, 127.17, 117.59, 116.34, 115.55, 115.34, 108.84, 103.95, 68.98, 60.63. HRMS (+ESI): Found *m/z* 360.10063, [M + Na]$^+$. C$_{20}$H$_{16}$FNO$_3$Na [360.10119].

3-(4-Fluorophenyl)-4-(quinolin-3-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol (**15c**). Brown gum, yield: 87%. IR (neat) 2923, 2798, 1598 cm^{-1}. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.12 (s, 1H), 8.84 (d, *J* = 2.7 Hz, 1H), 7.99–7.85 (m, 2H), 7.88–7.78 (m, 1H), 7.60 (ddd, *J* = 8.4, 6.9, 1.5 Hz, 1H), 7.52 (ddd, *J* = 8.2, 6.9, 1.3 Hz, 1H), 7.51–7.42 (m, 2H), 7.21–7.07 (m, 2H), 6.90 (d, *J* = 8.7 Hz, 1H), 6.36–6.26 (m, 2H), 5.24 (d, *J* = 3.1 Hz, 1H), 4.61 (dd, *J* = 11.2, 3.0 Hz, 1H), 4.30 (dd, *J* = 11.2, 2.7 Hz, 1H). ^{13}C NMR (101 MHz, DMSO-d_6) δ 163.04, 160.63, 153.02, 147.79, 146.65, 143.82, 141.66, 135.59, 135.56, 129.56, 129.48, 128.86, 128.66, 128.07, 127.65, 127.54, 124.89, 122.10, 120.05, 115.83, 115.62, 109.37, 104.22, 67.68, 59.68. HRMS (+ESI): Found *m/z* 373.13476, [M + H]$^+$. C$_{23}$H$_{18}$FN$_2$O$_2$ [373.13523].

4. Conclusions

In summary, we developed a facile and efficient approach to synthesise derivatives of a novel 4-aryl-3,4-dihydro-2*H*-1,4-benzoxazine scaffold with anticancer activity. A total of 29 novel analogues were designed and synthesised for preliminary biological screening. Ten of the synthesised molecules showed positive results against the proliferation of MIA PaCa-2, MDA-MB-231 and PC-3 cancer cells. Compound **14f** was identified as a promising lead molecule for further in-depth studies, and subsequent dose-response experiments revealed IC$_{50}$ values of 7.84–16.2 μM against a panel of five cancer cell lines. Preliminary SAR studies suggested that hydroxyl groups on rings A and B and a 4-amino group on ring C were important for anticancer activity. However, it should be noted that the 1,4-benzoxazines were synthesised as racemic mixtures in this study. Future investigations could be conducted to understand the effect of chirality on antiproliferative properties.

Additionally, the precise mechanism of the anticancer activity remains to be explored. Investigating the effects of these compounds on particular signalling and metabolic systems, such as estrogen receptor, could provide an explanation for the established SAR and generate suggestions for the further structural improvement of these molecules.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424. [CrossRef] [PubMed]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA Cancer J. Clin.* **2020**, *70*, 7–30. [CrossRef] [PubMed]
3. Viale, P.H. The American Cancer Society's Facts & Figures: 2020 Edition. *J. Adv. Pract. Oncol.* **2020**, *11*, 135–136. [CrossRef]
4. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. *Trends Pharmacol. Sci.* **2005**, *26*, 178–182. [CrossRef] [PubMed]
5. Lu, J.J.; Pan, W.; Hu, Y.J.; Wang, Y.T. Multi-target drugs: The trend of drug research and development. *PLoS ONE* **2012**, *7*, e40262. [CrossRef] [PubMed]
6. Hawash, M. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. *Biomolecules* **2022**, *12*, 1843. [CrossRef] [PubMed]
7. Wähälä, K.; Koskimies, J.K.; Mesilaakso, M.; Salakka, A.K.; Leino, T.K.; Adlercreutz, H. The Synthesis, Structure, and Anticancer Activity of *cis*- and *trans*-4′,7-Dihydroxyisoflavan-4-ols. *J. Org. Chem.* **1997**, *62*, 7690–7693. [CrossRef]
8. Lund, T.D.; Blake, C.; Bu, L.; Hamaker, A.N.; Lephart, E.D. Equol an isoflavonoid: Potential for improved prostate health, in vitro and in vivo evidence. *Reprod. Biol. Endocrinol.* **2011**, *9*, 4. [CrossRef]
9. Wang, X.; McKernan, R.; Kim, K.H.; Alvero, A.B.; Whiting, A.; Thompson, J.A.; Mor, G.; Saif, M.W.; Husband, A.J.; Brown, D.M.; et al. Triphendiol (NV-196), development of a novel therapy for pancreatic cancer. *Anticancer Drugs* **2011**, *22*, 719–731. [CrossRef]
10. Christiansen, L.B.; Wenckens, M.; Bury, P.S.; Gissel, B.; Hansen, B.S.; Thorpe, S.M.; Jacobsen, P.; Kanstrup, A.; Jørgensen, A.S.; Nærum, L.; et al. Synthesis and biological evaluation of novel thio-substituted chromanes as high-affinity partial agonists for the estrogen receptor. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 17–19. [CrossRef]
11. Stevenson, A.J.; Ager, E.I.; Proctor, M.A.; Škalamera, D.; Heaton, A.; Brown, D.; Gabrielli, B.G. Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. *Sci. Rep.* **2018**, *8*, 5144. [CrossRef]
12. Matralis, A.N.; Katselou, M.G.; Nikitakis, A.; Kourounakis, A.P. Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents. *J. Med. Chem.* **2011**, *54*, 5583–5591. [CrossRef] [PubMed]
13. Blattes, E.; Lockhart, B.; Lestage, P.; Schwendimann, L.; Gressens, P.; Fleury, M.-B.; Largeron, M. Novel 2-Alkylamino-1,4-benzoxazine Derivatives as Potent Neuroprotective Agents: Structure−Activity Relationship Studies. *J. Med. Chem.* **2005**, *48*, 1282–1286. [CrossRef] [PubMed]
14. Burton, G.A.; Rehwinkel, H.; Jaroch, S.; Hoelscher, P.; Suelzle, D.; Hillmann, M.; McDonald, F.M. Benzoxazine and Benzothiazine Derivatives and Their Use in Medicine. WO/2000/017173, 30 March 2000.
15. Bollu, R.; Palem, J.D.; Bantu, R.; Guguloth, V.; Nagarapu, L.; Polepalli, S.; Jain, N. Rational design, synthesis and anti-proliferative evaluation of novel 1,4-benzoxazine-[1,2,3]triazole hybrids. *Eur. J. Med. Chem.* **2015**, *89*, 138–146. [CrossRef]

16. Das, B.C.; Madhukumar, A.V.; Anguiano, J.; Mani, S. Design, synthesis and biological evaluation of 2H-benzo[b][1,4]oxazine derivatives as hypoxia targeted compounds for cancer therapeutics. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4204–4206. [CrossRef] [PubMed]

17. La, D.S.; Belzile, J.; Bready, J.V.; Coxon, A.; DeMelfi, T.; Doerr, N.; Estrada, J.; Flynn, J.C.; Flynn, S.R.; Graceffa, R.F. Novel 2, 3-dihydro-1, 4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. *J. Med. Chem.* **2008**, *51*, 1695–1705. [CrossRef] [PubMed]

18. Ilic, M.; Ilas, J.; Dunkel, P.; Matyus, P.; Bohac, A.; Liekens, S.; Kikelj, D. Novel 1,4-benzoxazine and 1,4-benzodioxine inhibitors of angiogenesis. *Eur. J. Med. Chem.* **2012**, *58*, 160–170. [CrossRef]

19. Aicher, T.D.; Van Huis, C.A.; Hurd, A.R.; Skalitzky, D.J.; Taylor, C.B.; Beleh, O.M.; Glick, G.; Toogood, P.L.; Yang, B.; Zheng, T. Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer. *J. Med. Chem.* **2021**, *64*, 13410–13428. [CrossRef]

20. Dong, F.D.; Liu, D.D.; Deng, C.L.; Qin, X.C.; Chen, K.; Wang, J.; Song, H.R.; Ding, H.W. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kalpha inhibitors. *Bioorg. Med. Chem.* **2018**, *26*, 3982–3991. [CrossRef]

21. Yan, G.; Pu, C.; Lan, S.; Zhong, X.; Zhou, M.; Hou, X.; Yang, J.; Shan, H.; Zhao, L.; Li, R. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors. *Eur. J. Med. Chem.* **2019**, *178*, 667–686. [CrossRef]

22. Jana, A.K.; Singh, J.; Ganesher, A.; Kumar, A.; Banerjee, A.; Kumar, D.; Verma, S.K.; Sharma, A.K.; Bhatta, R.S.; Konwar, R. Tyrosine-Derived Novel Benzoxazine Active in a Rat Syngenic Mammary Tumor Model of Breast Cancer. *J. Med. Chem.* **2021**, *64*, 16293–16316. [CrossRef] [PubMed]

23. Dickson, J.K.; Gungor, T.; Yang, W. 3-Aryl-hydroxybenzoxazines and 3,4-Dihydro-3-aryl-hydroxybenzoxazines as Selective Estrogen Receptor Beta Modulators. US7015219B2, 21 March 2006.

24. Turner, J.V.; Agatonovic-Kustrin, S.; Glass, B.D. Molecular aspects of phytoestrogen selective binding at estrogen receptors. *J. Pharm. Sci.* **2007**, *96*, 1879–1885. [CrossRef] [PubMed]

25. Saif, M.W.; Heaton, A.; Lilischkis, K.; Garner, J.; Brown, D.M. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). *Cancer Chemother. Pharmacol.* **2017**, *79*, 303–314. [CrossRef] [PubMed]

26. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.* **2017**, *7*, 42717. [CrossRef] [PubMed]

27. Hannah, R.; Beck, M.; Moravec, R.; Riss, T. CellTiter-Glo™ Luminescent cell viability assay: A sensitive and rapid method for determining cell viability. *Promega Cell Notes* **2001**, *2*, 11–13.

28. Felicetti, T.; Cannalire, R.; Burali, M.S.; Massari, S.; Manfroni, G.; Barreca, M.L.; Tabarrini, O.; Schindler, B.D.; Sabatini, S.; Kaatz, G.W.; et al. Searching for Novel Inhibitors of the S. aureus NorA Efflux Pump: Synthesis and Biological Evaluation of the 3-Phenyl-1,4-benzothiazine Analogues. *ChemMedChem* **2017**, *12*, 1293–1302. [CrossRef] [PubMed]

29. Tian, Y.; Wang, X.; Xiao, Q.; Sun, C.; Yin, D. Synthesis of Dihydrobenzoheterocycles through Al(OTf)3-Mediated Cascade Cyclization and Ionic Hydrogenation. *J. Org. Chem.* **2014**, *79*, 9678–9685. [CrossRef] [PubMed]

30. Wei, S.; Feng, X.; Du, H. A metal-free hydrogenation of 3-substituted 2H-1,4-benzoxazines. *Org. Biomol. Chem.* **2016**, *14*, 8026–8029. [CrossRef]